Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT02227251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02227251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 30, 2014
Completion date
December 31, 2026
Enrollment
244 (estimated)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma